A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia

• Published in: Blood Vol. 132; no. 21; pp. 2249 - 2259
• Main Authors: Chen, Lisa S., Bose, Prithviraj, Cruz, Nichole D., Jiang, Yongying, Wu, Qi, Thompson, Philip A., Feng, Shuju, Kroll, Michael H., Qiao, Wei, Huang, Xuelin, Jain, Nitin, Wierda, William G., Keating, Michael J., Gandhi, Varsha
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 22.11.2018; American Society of Hematology
• Subjects: Adenine - analogs & derivatives; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors; Agammaglobulinaemia Tyrosine Kinase - metabolism; Aged; Clinical Trials and Observations; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Male; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - administration & dosage; Pyrazoles - therapeutic use; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Signal Transduction - drug effects; Treatment Outcome

Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton's tyrosine kinase (BTK) protein levels in CLL cells after 1 cycle of ibrutinib, suggesting ibrutinib dose could be lowered after the first cyc...